Premium
CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
Author(s) -
Nayak L.,
Iwamoto F.M.,
Ferreri A.J.,
Santoro A.,
Singer S.,
Batlevi C.,
Batchelor T.,
Rubenstein J.,
Johnston P.,
Ramchandren R.,
Soussain C.,
Drappatz J.,
Becker K.,
WitzensHarig M.,
Illerhaus G.,
Herrera A.,
Masood A.,
Shipp M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2440_2
Subject(s) - medicine , primary central nervous system lymphoma , nivolumab , refractory (planetary science) , lymphoma , oncology , tolerability , cancer research , cancer , immunotherapy , adverse effect , biology , astrobiology